Alembic Limited (IN:ALEMBICLTD)
:ALEMBICLTD
Want to see IN:ALEMBICLTD full AI Analyst Report?
Top Page
Alembic Limited
(ALEMBICLTD)
Select Model
Select Model
Rating:72Outperform
Price Target:
₹97.00
▼(-6.19% Downside)
Action:Reiterated
Date:05/23/26
The score is driven primarily by strong financial positioning (especially the very low leverage) and an attractive valuation (low P/E with a meaningful dividend yield). These positives are partially offset by mixed technicals (price below key longer-term averages) and historical volatility in cash flow and earnings quality, despite improvement in 2026.
Positive Factors
Conservative Balance Sheet
Alembic's minimal net debt and stable asset base provide durable financial flexibility. Low leverage reduces solvency risk, supports sustained R&D and capex funding, and makes the company better able to weather industry cycles or absorb one-off shocks without eroding core operations.
Negative Factors
Earnings Quality Concerns
Reported net income being unusually high relative to revenue suggests material non-operating gains or accounting effects. That reduces the reliability of reported earnings as a guide to recurring operating profitability and complicates forecasting of sustainable cash flows and returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Alembic's minimal net debt and stable asset base provide durable financial flexibility. Low leverage reduces solvency risk, supports sustained R&D and capex funding, and makes the company better able to weather industry cycles or absorb one-off shocks without eroding core operations.
Read all positive factors
Alembic Limited (ALEMBICLTD) vs. iShares MSCI India ETF (INDA)
Market Cap
₹22.38B
Dividend Yield2.36%
Average Volume (3M)22.23K
Price to Earnings (P/E)7.1
Beta (1Y)1.46
Revenue Growth8.16%
EPS Growth2.12%
CountryIN
Employees285
SectorHealthcare
Sector Strength45
IndustryReal Estate - Development
Share Statistics
EPS (TTM)12.62
Shares Outstanding256,781,830
10 Day Avg. Volume15,327
30 Day Avg. Volume22,227
Financial Highlights & Ratios
PEG Ratio2.67
Price to Book (P/B)0.74
Price to Sales (P/S)7.59
P/FCF Ratio17.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Alembic Limited Business Overview & Revenue Model
Company Description
Alembic Limited engages in the manufacturing and marketing of fermentation and chemistry based active pharmaceuticals ingredients (API). It operates through API and Real Estate segments. The company is also involved in the construction of resident...
How the Company Makes Money
Alembic Limited primarily makes money by selling pharmaceutical products, with revenue largely derived from (1) finished dosage formulations (branded and/or generic medicines) sold into the Indian market and exported to regulated and other interna...
Alembic Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.24B | 2.40B | 2.22B | 1.57B | 1.18B | 713.69M |
| Gross Profit | 1.58B | 1.14B | 1.53B | 872.46M | 702.07M | 404.50M |
| EBITDA | 1.72B | 904.60M | 1.69B | 1.12B | 939.86M | 1.03B |
| Net Income | 3.24B | 3.17B | 3.11B | 2.69B | 1.91B | 2.22B |
Balance Sheet | ||||||
| Total Assets | 27.27B | 25.90B | 25.03B | 23.29B | 22.05B | 26.32B |
| Cash, Cash Equivalents and Short-Term Investments | 888.10M | 999.00M | 582.80M | 129.05M | 464.09M | 270.77M |
| Total Debt | 125.80M | 106.40M | 144.50M | 91.49M | 0.00 | 0.00 |
| Total Liabilities | 1.91B | 1.44B | 1.64B | 1.43B | 1.27B | 1.35B |
| Stockholders Equity | 25.36B | 24.45B | 23.39B | 21.86B | 20.78B | 24.97B |
Cash Flow | ||||||
| Free Cash Flow | 257.50M | 1.06B | 356.00M | -336.03M | 130.35M | -535.60M |
| Operating Cash Flow | 489.60M | 1.82B | 863.70M | 226.87M | 388.52M | -177.47M |
| Investing Cash Flow | 135.10M | -1.18B | -265.80M | 258.36M | 72.96M | 188.48M |
| Financing Cash Flow | -639.70M | -652.20M | -583.40M | -481.94M | -463.88M | -58.16M |
Alembic Limited Technical Analysis
Negative
103.40
Price Trends
86.43
Positive
90.62
Negative
96.53
Negative
Market Momentum
-0.40
Positive
43.60
Neutral
16.09
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALEMBICLTD, the sentiment is Negative. The current price of 103.4 is above the 20-day moving average (MA) of 90.44, above the 50-day MA of 86.43, and above the 200-day MA of 96.53, indicating a neutral trend. The MACD of -0.40 indicates Positive momentum. The RSI at 43.60 is Neutral, neither overbought nor oversold. The STOCH value of 16.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALEMBICLTD.
Alembic Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹398.73B | 42.51 | ― | 0.28% | 7.91% | 54.70% | |
72 Outperform | ₹22.38B | 7.10 | ― | 2.36% | 8.16% | 2.12% | |
69 Neutral | ₹651.90B | 28.57 | ― | 0.80% | 13.48% | 6.18% | |
68 Neutral | ₹833.83B | 23.64 | ― | 0.33% | 6.08% | 0.77% | |
62 Neutral | ₹148.33B | 21.45 | ― | 1.28% | 10.08% | 15.65% | |
53 Neutral | ₹672.39B | 60.27 | ― | 0.24% | 25.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ALEMBICLTD
Alembic Limited
87.87
-20.35
-18.80%
IN:ALKEM
Alkem Laboratories Ltd.
5,497.80
451.16
8.94%
IN:APLLTD
Alembic Pharmaceuticals Limited
735.10
-270.95
-26.93%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,430.90
287.69
25.17%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,274.25
820.07
56.39%
IN:IPCALAB
IPCA Laboratories Limited
1,512.90
90.92
6.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.